Telix Pharmaceuticals has entered a $20 million (18 million euros) agreement to acquire the U.K.-based Lightpoint Medical.
Lightpoint will become a new unit within Telix to support development of its medical device and software technology. The deal includes an additional $15 million (14 million euros) earn-out payable in cash or equity on Lightpoint's achievement of certain milestones relating to the development and commercialization of its Sensei probe, Telix said.
Sensei is a miniature robotic gamma probe for intracavital use that provides radiopharmaceutical-based surgical guidance by enabling intraoperative detection of cancer in real-time, the company said.
In other news, Telix has opened a radiopharmaceutical production facility located near Brussels colloquially referred to as "Radiopharma Valley." The 2,800-square-meter facility includes a 965-square-meter radiopharmacy, nine clean rooms, two purification suites, two R&D laboratories, two quality control laboratories, and two cyclotron vaults.
The facility is now among Europe's largest radiopharmaceutical production facilities and will serve as Telix's primary site for radioisotopes and commercial and clinical products for patients in Europe, the Middle East, and Africa, the company noted.
